Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use

Area of Science:

• Molecular Biology
• Genetics
• Oncology

Background:

• Poly(ADP-ribose) polymerase (PARP) proteins are crucial for DNA repair and other cellular processes.
• PARP inhibitors (PARPi) are effective in cancers with homologous recombination (HR) DNA repair defects, such as BRCA1/2 mutations.
• This synthetic lethality approach is limited to cancers with existing HR deficiencies.

Purpose of the Study:

• To explore the potential of inducing therapeutic BRCAness through various molecular pathways.
• To expand the utility of PARPi beyond tumors with inherent BRCAness.
• To discuss strategies for achieving PARPi synthetic lethality in a broader range of cancers.

Main Methods:

• Review of preclinical studies on PARP inhibitors and DNA repair pathways.
• Analysis of mechanisms by which small molecules can induce BRCAness.
• Discussion of therapeutic strategies targeting molecular pathways to create synthetic lethality.

Main Results:

• PARPi demonstrate tumor-specific cytotoxicity in cancers with BRCA1/2 mutations due to defective homologous recombination.
• The 'BRCAness' phenotype, characterized by impaired HR, explains PARPi sensitivity.
• Emerging evidence suggests various small molecule agents can induce therapeutic BRCAness.

Conclusions:

• Targeting molecular pathways to induce BRCAness offers a promising strategy to broaden PARPi therapeutic applications.
• This approach could enhance the efficacy of PARPi in a wider spectrum of cancers.
• Further research into inducing therapeutic BRCAness is warranted to optimize PARPi-based cancer treatments.